Hypothesizing that the onset of bevacizumab‐induced HTN during treatment involves successful inhibition of the VEGF pathway, studies have examined the relationship between HTN and outcome among patients treated with bevacizumab. The gene discussed is VEGFA; the disease is hypertensive disorder.